Category Archives: Psoriasis

Psoriasis and psoriatic arthritis do share one common symptom: fatigue, which is likely due to high levels of inflammation, according to NYU Langone Health.

About 7 million Americans have psoriasis, and only a fraction of them will ever develop psoriatic arthritis, according to the Cleveland Clinic. Estimates vary depending on the source, but the Centers for Disease Control and Prevention (CDC) says that roughly 10% to 20% of people with psoriasis go on to develop psoriatic arthritis.

In contrast, the Cleveland Clinic estimates that up to 30% of people with psoriasis will develop psoriatic arthritis. That said, having psoriasis is the single most significant risk factor for developing psoriatic arthritis, Naomi Schlesinger, M.D., chief of the Division of Rheumatology at Rutgers Robert Wood Johnson Medical School, tells SELF.

If you have psoriasis, its extremely important to watch for any joint symptoms, such as swelling, pain, or stiffnessthe most common signs of psoriatic arthritisand report them to your physician, says David Giangreco, M.D., a rheumatologist at Northwestern Medicine Delnor Hospital. Psoriatic arthritis is a progressive disease, meaning it can get worse over time. And if you happen to get diagnosed with psoriatic arthritis in its early stages, then your doctor can prescribe treatments that slow the diseases progression and help preserve your joints.

Medical experts used to believe that people with psoriasis could only develop psoriatic arthritis within 10 years of their initial psoriasis diagnosis, according to the Cleveland Clinic. However, studies have shown that this isnt true. In fact, up to 15% of people with both diseases actually experienced their psoriatic arthritis symptoms first, according to the Cleveland Clinic. Some people may develop psoriatic arthritis before psoriasis, and others may have had psoriasis for years without realizing it, according to Dr. Giangreco. Psoriasis can remain hidden from patients on the back of the scalp or buttock area and go unnoticed for long periods of time, Dr. Giangreco tells SELF. If you have psoriatic arthritis and suddenly notice changes in your skin and nails, then you dont want to rule out the possibility of psoriasis. Rarely do people have psoriatic arthritis without getting psoriasis, too, according to the U.S. National Library of Medicine.

Psoriasis and psoriatic arthritis are clearly connected, but experts dont know why some people develop both conditions. However, genetics appears to be involved. Researchers have pinpointed a family of genes called the human leukocyte antigen (HLA) complex as a possible contributor to psoriasis and psoriatic arthritis, according to the U.S. National Library of Medicine. (The HLA complex helps your immune system recognize your bodys proteins compared to proteins from foreign pathogens such as viruses and bacteria, the organization explains.) People with psoriasis or psoriatic arthritis have HLA genes that are different from people who dont have either condition, according to a May 2021 paper published in The Journal of Rheumatology. And people with psoriasis who have a specific HLA gene mutation are more likely to develop psoriatic arthritis, according to the same paper.

Medical experts also believe that psoriatic arthritis may be inherited. About 40% of people with psoriatic arthritis have a family member with either psoriasis or psoriatic arthritis, according to the U.S. National Library of Medicine.

People with either condition frequently say that their health informs their decision-making, from the clothes they buy to their careers. Thats because both conditions can drastically change your life, making it difficult to sleep, work, and do the things you love, like playing with your children or baking. For example, when you have a psoriasis flare, even rolling over in bed or wearing tight clothing can be extremely painful. Some people with psoriasis choose clothing that hides their flares to avoid getting comments about their skins appearance. Similarly, joint pain from psoriatic arthritis can make it really hard to sit on the floor with your kids, get out of bed for work, or follow through on plans. This can all become overwhelming, and understandably make some people feel self-conscious about their health conditions.

There are no cures for either disease, but an effective treatment plan can minimize symptoms for both psoriasis and psoriatic arthritis. With psoriasis, doctors generally prescribe treatments that prevent your skin cells from growing too quickly, according to the Mayo Clinic. There are many treatment options for this, including creams, light therapy, or oral or injected medications, the Mayo Clinic explains.

As for psoriatic arthritis, treatments generally focus on controlling inflammation to minimize your joint pain and damage. Your doctor might suggest pharmacological options that target your immune system to lower inflammation, along with exercise or other lifestyle modifications, according to the Mayo Clinic. With each condition, the best treatment depends on your particular situation.

Both conditions can cause a lot of physical and emotional painbut you can find some relief with the right treatment plan. If you think you have psoriasis or psoriatic arthritis (or both), talk to your doctor about how you can live more comfortably.

Related:

More:
How Are Psoriasis and Psoriatic Arthritis Connected? - Self

@cienaraenelson / Instagram

Psoriasis is one of those conditions that can be easy to shrug off if youve never experienced it. Even though we write about skin issues all the time, even we have had fleeting thoughts along the lines of Kim Kardashian has it, and wed never have been able to tell.

Of course, the truth is that having psoriasis is more than getting occasional itchy red patches of skin. Its an autoimmune disease with symptoms that can be quite serious. And for more than five years, Los Angelesbased actress Ciena Rae Nelson has reminded the world of that on Instagram.

Nelson started sharing her journey with psoriasis in 2016, posting a selfie in which her skin is red and inflamed after a psoriasis flare-up. This is me 2 years ago just before I went to the hospital for severe dehydration and a fever, she wrote. Skin conditions are not cosmetic issues.

The same day, she shared a side-by-side selfie that showed her made up and nearly flawless in the left image, and red and blotchy in the right, thanks to photo editing that allowed her to increase the saturation of that picture to reveal the skin condition beneath. Most people looked at the left in person and didnt notice much but dry spots here and there, not noticing what was really underneath, she wrote. #psoriaticarthritis is an #invisibleillness and sometimes so is psoriasis (chronic itchiness and chronic fatigue). Not everything is as bad as it looks and sometimes things aremuch worse.

But while the posts were new, Nelsons psoriasis was anything but: Shes been living with psoriasis for nearly my entire life, she wrote in an Instagram post for the National Psoriasis Foundation, which means that I dont really know what life is like without it. As a child with psoriasis, she often felt isolated. I didnt know anyone who understood what I was going through, she wrote. And while her family was supportive, I always felt that unless they had it, theyd never really get it.

Story continues

After her first posts about it in 2016, there was an influx of support from people from all around the world who were going through something similar, she wrote. I started meeting up with people who reached out just to connect about psoriasis, which was something I had never done before. In fact, many of the people I met had neverspoken to someone with psoriasis before.

Since then Nelson has been a vocal social advocate for psoriasis awareness. She wants people to know theyre not alone. For people who suffer with chronic illness, it is so important to be able to connect with other people who have experienced what we have, in order to feel validated and understood, she wrote. Society tells us that we have to show up in the world, at work, at school, with our friends, just like everyone else does. But we are not like everyone else. And so if we are not careful, we can easily end up overexerting ourselves at the expense of our quality of life.

Nelson talks openly about how the condition affects not only her skin but also her mental health. Psoriasis can take a toll on your emotional well-being. Not only is stress a trigger for psoriasis, but, as Nelson shares, the disease can cause stress. Psoriasis can also cause depression.

In a 2019 post, Nelson shared that shed had a breakdown about my skin and thought very seriously for the first time in a long time about going back on medication, but I started therapy instead. Therapy, she writes, has been important in helping her learn to live with psoriasis. Are any of you in therapy? Nelson asked her followers. She pointed out that people with Psoriasis are twice as likely to become depressed as the rest of the population, and therapy can really help. So can meditation, exercise, plenty of sleep, and a nutritious diet, according to the National Psoriasis Foundation.

Nelson admits that sometimes psoriasis gets the better of her and makes her angry. I am losing days of my life to beds and antihistamines, she wrote last year. But that raw vulnerability helps her connect with other people who suffer with psoriasis and allows her to relate to them.

If you have felt this way, youre not alone, she wrote in another post last year. Theres no use in comparing your journey to anyone elses. Youre in a relay race all by yourself and you have to keep showing up for you. If today, it takes all the strength you can gather just to do your morning routine, and that takes you hours instead of minutes, dont worry. Youre winning. Keep going.

But that realness never comes without hope. Nelson knows she and those who have psoriasis will have good days and bad days. (And there are treatment options people can explore to have those good days!) But, she writes, they should never let psoriasis get in the way of living their lives.

Being chronically ill sometimes means you have to mourn the you that you were before your health began to decline, and accept a new normal, Nelson wrote last year. You have to do this because you cant live your life waiting to be normal. Viewing it as some purgatory between good and bad health. You have to live now, to the best of your ability, no matter the circumstance.

Originally Appeared on Glamour

Follow this link:
These Powerful Photos Capture What Its Really Like to Have Psoriasis - Yahoo Lifestyle

TOKYO--(BUSINESS WIRE)--First paragraph, third sentence of release dated May 20, 2021, should read: Those clinical trials are conducted in collaboration with Dong-A Socio Holdings (Headquarters: Seoul, Korea, CEO: JUNG Jae-Hun, Dong-A). (instead of Those clinical trials are conducted in collaboration with Dong-A Socio Holdings (Headquarters: Seoul, Korea, CEO: Jong Hyun Han, Dong-A).).

The updated release reads:

MEIJI SEIKA PHARMA: PROMISING RESULTS OF PHASE I CLINICAL TRIAL OF DMB-3115, A PROPOSED USTEKINUMAB BIOSIMILAR, AND INITIATION OF PHASE III CLINICAL TRIAL IN PATIENTS WITH PLAQUE PSORIASIS

Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo, Japan, President and Representative Director: Daikichiro Kobayashi, Meiji) today announced that the bioequivalence of DMB-3115, a proposed ustekinumab biosimilar, has been demonstrated in phase I clinical trial compared to the reference products marketed in Europe and the United States. Meiji also announced the initiation of phase III multi-regional clinical trial in patients with plaque psoriasis. Those clinical trials are conducted in collaboration with Dong-A Socio Holdings (Headquarters: Seoul, Korea, CEO: JUNG Jae-Hun, Dong-A).

DMB-3115 is a proposed biosimilar to ustekinumab, a recombinant monoclonal antibody for the treatment of patients with several inflammatory diseases such as plaque psoriasis, psoriatic arthritis, Crohns disease and ulcerative colitis. Meiji and Dong-A are co-developing DMB-3115 under the strategic collaboration partnership agreement on biosimilars signed in September 2011. DMB-3115 is produced by using Sp2/0 cells, the same as those used in reference products to achieve high similarity in quality aspects.

The Phase I clinical trial is a randomized double-blind, three-arm, single-dose study to compare pharmacokinetics, safety and tolerability of DMB-3115 with its reference products (US- and EU-marketed products) in 296 healthy volunteers at a single site in Europe. As a result, bioequivalence of DMB-3115 compared to reference products was demonstrated in terms of several pharmacokinetic parameters. A single subcutaneous injection of DMB3115 in healthy volunteers was well tolerated. The reported adverse events corresponded with the known safety profile of ustekinumab. There were no new unexpected adverse events.

The Phase III multi-regional clinical trials in patients with plaque psoriasis, with the target number of patient being 590, has been initiated in Europe and the United States. In this study, efficacy, safety, pharmacokinetics and immunogenicity of DMB-3115 and reference products (45 mg or 90mgsubcutaneous injection, respectively) are being compared in randomized, double-blinded controlled trial.

Meiji aims to contribute to medical care and society by developing and launching biosimilars with high quality as well as biologics products.

View post:
CORRECTING and REPLACING Meiji Seika Pharma: Promising Results of Phase I Clinical Trial of DMB-3115, a Proposed Ustekinumab Biosimilar, and...

Before the modernization of medicine, symptoms of diseases like psoriatic arthritis (PsA) were addressed in interesting ways. In ancient Greece, symptoms were treated with tar and topical arsenic, prescribed by Hippocrates.1 In medieval times, PsA was thought to be contagious, and patients were put in isolation and treated with harmful, ineffective toxins, like sulfur and mercury.1

Medicine has come a long way since then, and although there is still no cure for PsA, weve witnessed significant breakthroughs in the scientific understanding of the disease since the coining of the term in 1860.1

In the US, more than 1 million people are living with PsA, a chronic rheumatologic disease characterized by joint pain, stiffness, and swelling.2,3 PsA can affect any part of the body, such as the fingertips and spine, or wherever your ligaments and tendons connect to the bone.3 Psoriatic arthritis affects approximately 30% of people with psoriasis (PsO), an inflammatory skin disease, and patients with PsA also experience PsO skin lesions and plaques.3

Continue Reading

As we experience rapid advancements in technology from wearables to data science, and combine these advancements with the recent influx of new scientific insights, we are on the verge of another revolution in rheumatic disease medicine.

During the last century, weve learned more about PsA manifestations and taken significant strides in patient care. Previously, physicians treated patients with PsA just as they would patients with rheumatoid arthritis, a more common and well-known rheumatic disease of the joints. In doing so, swollen joints were the only issue of PsA that were being addressed.

We now know that PsA is a heterogeneous disease affecting different domains of the body with varying degrees of severity for each patient some patients have minimal skin issues and more arthritis signs and symptoms, and others, vice versa. Symptoms of PsA go beyond skin and joints too, with many patients experiencing debilitating symptoms, like fatigue and anxiety, which are now being considered when establishing a treatment plan.

Treatment options for PsA can range from disease-modifying antirheumatic drugs (DMARDs) to nonsteroidal anti-inflammatory drugs (NSAIDs) to topical creams. Currently, these options focus on slowing the progression of joint pain to prevent permanent joint damage, combat inflammation, and attain skin clearance.

Although there are many treatment options available today, there is still an incredible unmet need in this space, and rheumatologists face the challenge of providing lasting remission to patients covering the whole diversity of disease manifestations.

To usher in the future of PsA therapy, we must cut across traditional disease area boundaries. First, we must continue to gain a better understanding of the patterns of this complex disease and its multifaceted symptoms. This will allow us to identify and unlock new pathways, mechanisms, and regimens for patients with limited or inadequate treatment options. We must continue to study our medicines in clinical practice settings and include patient, prescriber, and payer insights in our research efforts to reach a significantly broader population of patients with better and safer treatment approaches. Further, we must integrate patients into our decision-making process by engaging them in conversations about their treatment options.

Realworld evidence and patient-reported outcomes are leading to databases of information that are helping to advance therapeutic science. For example, we can now tap into these databases to gain new insights into a treatments safety and effectiveness and show trends across thousands of patients. We are also using connected devices to capture real-time patient health status, including monitoring movement, heart rate, and temperature. In rheumatic disease, wearable technology has enabled clinicians to assess patient flares using activity tracker data.4

A deeper understanding of disease patterns, pathogenesis, and patient-reported symptoms, paired with innovations in data and technology will create a winning combination that will lead to novel therapeutic options that restore immune balance and achieve remission.

Weve come a long way since the days of tar and arsenic treatment for PsA, but we still have a way to go. At Janssen, were driven by a relentless focus on the unmet patient need and are excited by the tremendous opportunity we have to alter the current immunology treatment landscape. Were rapidly advancing our data science capabilities, focusing on scientific insights and innovation, and keeping patients at the center of everything we do.

The future is exciting for us as scientists, but its especially meaningful and motivating to consider what the winning advancements could mean for the millions of people around the world living with PsA. How will we look back on todays treatments for PsA? I cant wait to find out.

Editors Note: To learn more about these efforts, please visit https://www.janssen.com/immunology.

See the original post here:
Redefining the Future of Psoriatic Arthritis Treatment - Rheumatology Advisor

The Chronic Plaque Psoriasis Market is expected to grow at a CAGR of 8.9% and is poised to reach US$XX Billion by 2027 as compared to US$XX Billion in 2020. The factors leading to this extraordinary growth is attributed to various market dynamics discussed in the report. Our experts have examined the market from a 360 degree perspective thereby producing a report which is definitely going to impact your business decisions.

In order to make a pre-order inquiry, kindly click on the link below:-https://decisivemarketsinsights.com/chronic-plaque-psoriasis-market/93055939/pre-order-enquiry

The Chronic Plaque Psoriasis Market research reports prepared by DECISIVE MARKETS INSIGHTS conveys a clear-cut idea to the readers about the key roles for in-depth analysis of the modern industrial outlook as well as the various effective strategies and futuristic plans for the betterment of the market growth. The report highlights the assorted governmental policies that are implemented for regulating and monitoring the financial set up as well as the economic system of the modern competitive market thereby providing a transparent idea about the overall scenario of the regulated market growth. The Chronic Plaque Psoriasis Market report contains a spread of economic, social, political, and technological factors thereby providing PESTEL analysis and BCG analysis of the modern competitive market.

To avail Sample Copy of report, visit @ https://decisivemarketsinsights.com/chronic-plaque-psoriasis-market/93055939/request-sample

Key Companies Operating in this MarketNovartis International AGSun Pharmaceutical Industries Ltd.Eli Lilly & companyAmgen Inc.Abb Vie Inc.Merck & Co.Pfizer Inc.Boehringer Ingelheim GmbHJanssen Biotech Inc.

Market by TypeTopicalsOralInjectable

Market by ApplicationHospital PharmaciesRetail PharmaciesE-Commerce

The Chronic Plaque Psoriasis Market report provides a detailed view about the growth of focus of the key market players for introducing innovative products which has eventually become one of the key trends in the modern marketing world and well as for future market growth. The report provides a 360-degree view of the varied modern marketing aspects as far as the scope is concerned as well as the different types of marketing parameters that has the potential to change the overall marketing scenario during the forecasted period of 2020-2027.

To inquire about the discount, kindly fill the form by clicking on the link below:-https://decisivemarketsinsights.com/chronic-plaque-psoriasis-market/93055939/request-discount

The report focuses on essential marketing points for business enhancement such as business revenue growth, ROI and CAGR on variety of market products. The report mentions the key reasons, the consequences of which have led to the way of huge opportunities for contemporary market growth. The report conveys vital information regarding the growth of modern market in different regions for estimating the worth of investment on a variety of market products as well as the opportunities that are yet to come in the forecasted period of 2020-2027 thus providing SWOT analysis of the modern competitive market. The report clearly depicts about the significant efforts made to gather accurate information on the modern marketing world as well as the diverse data collection through a lot of primary and secondary research processes. The report elaborately depicts the effective and efficient techniques that can be adopted to progress at par with the highly competitive modern marketing world and improvement of the potential profit of the businesses in the forecasted period of 2020-2027 thereby using the Porter Five Force Model effectively.

North America US, Mexico, Canada Europe Russia, Ukraine, France, Spain, Sweden, Norway, Germany, Finland, Poland, Italy, United Kingdom, Greece, Austria, Denmark, Switzerland, Netherlands, Belgium, Turkey, Luxembourg Asia-Pacific China, Japan, India, Australia, South Korea, Taiwan, Malaysia, Philippines, Thailand, Singapore South America- Brazil, Argentina, Peru, Chile Middle East and Africa Bahrain, Egypt, Israel, Kuwait, Qatar, Saudi Arabia, United Arab Emirates, South Africa

The Chronic Plaque Psoriasis Market report gives a close view on the adverse effects of the COVID 19 pandemic on the present market as well as the deadly second wave of the global pandemic and the negative impacts that it can cause to the modern marketing world such as social, geographical and economic disruptions. The Chronic Plaque Psoriasis Market report includes the information that are necessary for the readers to keep up the sustainability of modern market growth.

An insight into the market size and growth 2020-2027 CAGR: 2020 to 2027, calculating 2019 as the base year Detail information about the dominant players in this segment Demand and supply chain mapped to clearly evaluate the market Apart from primary and secondary research methodology, data triangulation method is used for a clear understanding of the report Analysis by best expert in the industry

Kindly contact us and our expert will get back to you within 30 minutes:

Decisive Markets InsightsSunil KumarSales HeadEmail sales@decisivemarketsinsights.comUS +18317045538UK +441256636046

Read the original post:
Chronic Plaque Psoriasis Report, Forecast 2020 2027, Upcoming Trend Analysis and Key Players Novartis International AG, Sun Pharmaceutical...

Coherent Market Insightshas announced new analysis on Psoriasis Treatment Market Status 2020-2027 which has been prepared based on an in-depth market analysis with inputs from industry experts and top vendors in the business. The report covers the market landscape and its development prospects over the coming years. The report also contains a discussion of the key vendors operating in this market.

The market analysis report speaks about thegrowth rate ofPsoriasis Treatment markettill2027 manufacturing process,key factorsdriving this market withsales, revenue, and price analysisof top manufacturers of Market,distributors, traders and dealersofPsoriasis TreatmentMarket.

Buy This Research Study Report For Quick Access@ https://www.coherentmarketinsights.com/insight/buy-now/99

Psoriasis Treatment Marketstudy coversmarket space,opportunitiesandthreats faced by the vendorsin thePsoriasis TreatmentMarket,opportunities, market risk and market overviewof the Market. The process is analysed thoroughly with respect three points, viz.raw material and equipment suppliers, various manufacturing associated costs (material cost, labour cost, etc.) and the actual process.

Psoriasis Treatment Market reports cover complete modest view with the market stake and company profiles of the important contestants working in the worldwide market. Also it offers a summary of product specification, production analysis, technology, product type, considering key features such as gross, gross margin, revenue & cost structure. The report helps the user to strengthen decisive power to plan their strategic moves to launch or expand their businesses by offering them a clear picture of this market.

If you are involved in the GlobalPsoriasis TreatmentMarketor intend to be, then this study will provide you comprehensive outlook. Its vital you keep your market knowledge up to date segmented by major players. If you have a different set of players/manufacturers according to geography or needs regional or country segmented reports we can provide customization according to your requirement.

Major Players Are: Glenmark Pharmaceuticals Limited, Sun Pharmaceuticals Industries Ltd., Cipla Ltd., Johnson & Johnson, Rowan Bioceuticals Private Limited, Stiefel Laboratories Inc. (GlaxoSmithKline plc), Win Medicare Pvt. Ltd., and Novartis AG

Major Point cover in this Psoriasis Treatment Market report are:

Reasons to buy this Psoriasis Treatment Market Report

The next part also sheds light on the gap between supply and consumption. Apart from the mentioned information,growth rateofPsoriasis Treatmentmarket in 2027 is alsoexplained.Additionally, type wise and application wise consumptiontables andfiguresof Psoriasis Treatment marketare also given.

Click Here To Get Sample Copy @ https://www.coherentmarketinsights.com/insight/request-sample/99

Points cover in Global Psoriasis Treatment Market Research Report:

Chapter 1: Overview of Global Psoriasis Treatment Market (2020-2027)

Definition Specifications Classification Applications Regions

Chapter 2: Market Competition by Players/Suppliers 2020 and 2027

Manufacturing Cost Structure Raw Material and Suppliers Manufacturing Process Industry Chain Structure

Chapter 3: Sales (Volume) and Revenue (Value) by Region (2020-2027)

Sales Revenue and market share

Chapter 4, 5 and 6: Global Psoriasis Treatment Market by Type, Application & Players/Suppliers Profiles (2020-2027)

Market Share by Type & Application Growth Rate by Type & Application Drivers and Opportunities Company Basic Information

Chapter 7, 8 and 9: Global Psoriasis Treatment Manufacturing Cost, Sourcing & Marketing Strategy Analysis

Key Raw Materials Analysis Upstream Raw Materials Sourcing Marketing Channel

Chapter 10 and 11: Psoriasis Treatment Market Effect Factors Analysis and Market Size (Value and Volume) Forecast (2020-2027)

Technology Progress/Risk Sales Volume, Revenue Forecast (by Type, Application & Region)

Chapter 12, 13, 14 and 15: Global Psoriasis Treatment Market Research Findings and Conclusion, appendix and data source

Methodology/Research Approach Data Source (Secondary Sources & Primary Sources) Market Size Estimation

About Coherent Market Insights

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Contact Us

Mr. ShahCoherent Market Insights1001 4th Ave, #3200Seattle, WA 98154Phone: US +12067016702 / UK +4402081334027Email: sales@coherentmarketinsights.com

Visit link:
Psoriasis Treatment Market to Showcase Healthy Expansion of CAGR During 20202027 KSU | The Sentinel Newspaper - KSU | The Sentinel Newspaper

Global Psoriatic Arthritis Treatment Market by Operating System, End User, Enterprise Solution Type, Industry Vertical and Enterprise Size: Opportunity Analysis and Industry Forecast, 20212027,

The osteoarthritis this is certainly psoriatic industry dimensions got appreciated at $7,860 million in 2018, and is also predicted to achieve at $13,744 million by 2026, joining a CAGR of 7.2per cent from 2019 to 2026.

Psoriatic joint disease try an inflammatory ailments that will be mutual with psoriasis, and thats classified inside the gang of spondyloarthritis. They impacts both our skin and program this is certainly musculoskeletal. It really is brought about because of hereditary and issue which happen to be ecological. Bloated feet, hands, and sensitive joints, decreased lumbar pain, pitted fingernails, and tightness were widespread the signs of psoriatic osteoarthritis. Analysis of psoriatic osteoarthritis is accomplished by studies such as for example combined substance examination, X-ray, rheumatoid aspect (RF), and resonance that will be magnetized (MRI). Psoriatic osteoarthritis can usually be treated with medication course such as for example NSAIDs, disease-modifying antirheumatic medication (DMARDs), biologics, and medication which happen to be immunosuppressant.

The psoriatic arthritis treatment market consists of the sale of psoriatic arthritis drugs used for the treatment of psoriatic arthritis by entities producing drugs for psoriatic arthritis. Psoriatic arthritis is a chronic degenerative condition associated with psoriasis. Symmetric psoriatic arthritis, asymmetric psoriatic arthritis, spondylitis, distal psoriatic arthritis, and arthritis mutilans are the different types of psoriatic arthritis. Rise in biological and biosimilar therapies, increase in prevalence of psoriatic arthritis, surge in R&D activities to develop novel drugs for the treatment of psoriatic arthritis, rise in demand for psoriatic arthritis treatment products, surge in geriatric population, strong pipeline of biosimilar & biologic products, and rise in awareness toward psoriatic arthritis treatment are the major factors that drive the growth of the global psoriatic arthritis treatment market.

The Covid-19 impact on demand of global Psoriatic Arthritis Treatment market is projected at global, regional & country level. Due to the Covid-19 pandemic lots of businesses have seen a decrease in their profit. The global Psoriatic Arthritis Treatment report offers actionable procurement intellect insights, tracing plans, and action strategies to ease hazards arising owing to Covid-19. Additionally, the trend and outlook of global Psoriatic Arthritis Treatment market is forecast in optimistic, balanced, and conventional view by taking into account of COVID-19.

Get Sample Copy of Psoriatic Arthritis Treatment Market Report at @https://www.apexmarketsresearch.com/sample/1057362

Psoriatic Arthritis Treatment Market competition by top manufacturers as follow:

The report presents the competitive landscape and corresponding detailed profiles of the ten major market players functional in the global Psoriatic Arthritis Treatment market. The selection of top market players has been based on their net sales, R&D expenditure, business segments, regional presence, distributors, and range of products in the market. The competitive analysis offered in the report will assist users in emphasis on the important parameters that will assist to set desired targets to stay competitive in the global Psoriatic Arthritis Treatment market.

AbbVie Inc., Amgen Inc., Bristol-Myers Squibb Company, Eli Lilly And Company., Johnson & Johnson., Merck & Co Inc., Mylan N.V, Novartis AG, Pfizer Inc., UCB S.A.,

Segmentation

The report offers a methodical and detailed analysis of the market segments that are based on main growth factors and key opportunities. The report divides the global Psoriatic Arthritis Treatment market by studying several parameters into corresponding segments and sub-segments. A detailed analysis of every segment will help the user to concentrate on the most lucrative segment in the market also provides a reason for the steady and low growth of other market segments.

By Drug TypeNSAIDsDMARDsBiologicsOthers

By TypePrescriptionOTC

By Route of AdministrationTopicalOralInjectable

Regional Outlook:

Based on geography the Psoriatic Arthritis Treatment market is segmented according to various region and countries as follows:

North America (Countries Includes: U.S., Canada)Europe (Countries Includes: UK, Germany, France, Rest of Europe)Asia Pacific (Countries Includes: China, Japan, India, Rest of Asia Pacific)Latin America (Countries Includes: Mexico, Brazil, Rest of Latin America)Middle East and Africa (Countries Includes: GCC Countries, South Africa, Rest of MEA)

In the region portion each region is considered and is explained in-depth along with the countries as to how the market is participating in the region, the impact of COVID-19 in the region and how it is affecting the Psoriatic Arthritis Treatment market. Thereby, all the relevant information along with graphical representation is provided in the regional section of the report.

Place Inquiry for Buying or Customization of Report @https://www.apexmarketsresearch.com/enquiry/1057362

Methodology

This Apex report is derived by detailed analysis, synthesis, and understanding of information about the global Psoriatic Arthritis Treatment market, generated from authenticate sources. Apex analysts produce set of information by applying primary and secondary research strategies to provide overall picture of the market. In addition, latest trends, key driving factors, opportunities, and potential threats have been considered to support the market forecast scenario.

Who will get benefit of this report?

The Apex reports are designed to offer several benefits to private equity firms, investors, small- and large-scale manufactures, distributors, suppliers operating in the market, and government and regulatory agencies. The scope of the report is designed to provide the most basic details of the Psoriatic Arthritis Treatment market, by which even start-ups can understand the market scenario more efficiently.

TOC for the Global Psoriatic Arthritis Treatment Market:

Chapter 1: Market Overview, Drivers, Restraints and Opportunities, Segmentation OverviewChapter 2: Market Competition by ManufacturersChapter 3: Production by RegionsChapter 4: Consumption by RegionsChapter 5: Production, By Types, Revenue and Market share by TypesChapter 6: Consumption, By Applications, Market share (%) and Growth Rate by ApplicationsChapter 7: Complete profiling and analysis of ManufacturersChapter 8: Manufacturing cost analysis, Raw materials analysis, Region-wise Manufacturing expensesChapter 9: Industrial Chain, Sourcing Strategy and Downstream BuyersChapter 10: Marketing Strategy Analysis, Distributors/TradersChapter 11: Market Effect Factors AnalysisChapter 12: Market ForecastChapter 13: Psoriatic Arthritis Treatment Research Findings and Conclusion, Appendix, methodology and data source

About Us:

We at Apex Market Research aim to be global leaders in qualitative and predictive analysis as we put ourselves in the front seat for identifying worldwide industrial trends and opportunities and mapping them out for you on a silver platter. We specialize in identifying the calibers of the markets robust activities and constantly pushing out the areas which allow our clientele base in making the most innovative, optimized, integrated and strategic business decisions in order to put them ahead of their competition by leaps and bounds. Our researchers achieve this mammoth of a task by conducting sound research through many data points scattered through carefully placed equatorial regions.

Contact Us:

Apex Market Research1st Floor, Harikrishna Building,Samarth Nagar, New Sanghvi,Pune- 411027 Indiatel: +91-8149441100 (GMT Office Hours)tel: +17738002974sales@apexmarketsresearch.com

View original post here:
Psoriatic Arthritis Treatment Market 2021 Industry Trend and Forecast 2026 | AbbVie Inc., Amgen Inc., Bristol-Myers Squibb Company, Eli Lilly And...

FRIENDSWOOD, Texas--(BUSINESS WIRE)-- Castle Biosciences Inc. (Nasdaq: CSTL), a dermatologic diagnostics company providing personalized genomic information to improve cancer treatment decisions, today announced its innovative pipeline initiative to develop a genomic test aimed at predicting systemic therapy response in patients with moderate to severe psoriasis, atopic dermatitis and related conditions.

Castle Biosciences has designed, developed and validated multiple genomic tests, including three dermatologic genomic tests, all of which are currently commercially available. These tests are designed to provide information for clinicians and patients to make personalized treatment decisions along the patient care continuum, including pre-diagnosis and following diagnosis, based on the biology of each patients disease. With the Companys pipeline test for psoriasis, atopic dermatitis and related conditions, Castle expands its dermatology focus from cancer to include inflammatory skin disease. This pipeline initiative is expected to produce a genomic test that predicts systemic therapy response to guide therapy selection in patients with moderate to severe psoriasis, atopic dermatitis and related conditions.

We are in an industry-leading position, as the only diagnostic company with a suite of dermatologic gene expression profile tests, said Derek Maetzold, president and chief executive officer of Castle Biosciences. We have demonstrated our ability to successfully develop, validate and bring to market clinically actionable, innovative tests. We start by identifying dermatologic diseases with high unmet clinical need. We then use the gene expression profile of an individual patients biology in an effort to develop gene expression profile tests designed to assist clinicians and their patients by better informing treatment to optimize health outcomes and reduce health care costs.

We are excited to expand our pipeline beyond cancer to other dermatologic diseases that significantly impact patients lives and have unanswered clinical questions. We are working with several leading experts in inflammatory skin diseases to develop a test that can predict a patients response to therapy for patients with moderate to severe psoriasis, atopic dermatitis and related conditions. Our goal is to shift systemic therapy selection such that the appropriate therapy is selected the first time. This goal is clinically and economically important, as the burden of cost for todays therapies are front loaded, and a significant amount is incurred within the first three months of treatment. If our test is able to guide therapy selection, based on the patients own disease biology, we believe we can help direct therapy selection decisions to start patients on potentially the most effective treatment sooner, while reducing the likelihood of a patient discontinuing or switching therapies, possibly resulting in a better utilization of healthcare resources.

Based upon our development and validation timelines, we believe that we can launch this pipeline test by the end of 2025, utilizing our well-established dermatologic sales channels, adding approximately $1.9 billion to our current estimated U.S. total addressable market.

Castle has initiated a 4,800 patient, prospective, multi-center clinical study to develop and validate this pipeline test. We expect to recruit approximately 50 participating centers from across the U.S.

About Psoriasis, Atopic Dermatitis and Related Conditions

Inflammatory skin disease accounts for a significant number of patient visits to both primary care and dermatology clinics across the U.S. every year. Psoriasis and atopic dermatitis are among the most common inflammatory skin conditions, and patient quality of life is severely impacted by these chronic diseases. Fortunately, systemic medications developed over the past 15 years have demonstrated a significant improvement in patients lives. In the U.S. alone, there are about 18 million patients diagnosed with psoriasis and atopic dermatitis, and approximately 450,000 patients annually are eligible for these systemic therapies. While there are now many effective treatments options available for those with moderate to severe disease, current clinical practice relies on a trial-and-error approach for therapy selection. To answer this unmet clinical need, Castle Biosciences is developing a gene expression profile test to predict response to systemic therapies for patients with moderate to severe psoriasis, atopic dermatitis and other related diseases. Personalized guidance for therapy selection and anticipated efficacy has the potential to improve patient health outcomes by enabling clinicians to select the best medication for their patients specific skin disease.

About Castle Biosciences

Castle Biosciences (Nasdaq: CSTL) is a commercial-stage dermatologic diagnostics company focused on providing physicians and their patients with personalized, clinically actionable genomic information to make more accurate treatment decisions. The Company currently offers tests for patients with cutaneous melanoma (DecisionDx-Melanoma, DecisionDx-CMSeq), cutaneous squamous cell carcinoma (DecisionDx-SCC), suspicious pigmented lesions (DecisionDx DiffDx-Melanoma) and uveal melanoma (DecisionDx-UM, DecisionDx-PRAME and DecisionDx-UMSeq). For more information about Castles gene expression profile tests, visit http://www.CastleTestInfo.com. Castle also has active research and development programs for tests in other dermatologic diseases with high clinical need, including its test in development to predict systemic therapy response in patients with moderate to severe psoriasis, atopic dermatitis and related conditions. Castle Biosciences is based in Friendswood, Texas (Houston), and has laboratory operations in Phoenix, Arizona. For more information, visit http://www.CastleBiosciences.com.

DecisionDx-Melanoma, DecisionDx-CMSeq, DecisionDx-SCC, DecisionDx DiffDx-Melanoma, DecisionDx-UM, DecisionDx-PRAME and DecisionDx-UMSeq are trademarks of Castle Biosciences, Inc.

Forward-Looking Statements

The information in this press release contains forward-looking statements and information within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, which are subject to the safe harbor created by those sections. These forward-looking statements include, but are not limited to, statements concerning the potential success of our pipeline initiative; potential improvements in patient treatment, optimized health outcomes and reduced healthcare costs attributable to any test developed by our pipeline initiative; anticipated timing for launch of our pipeline test; and the potential increase in our estimated U.S. total addressable market. The words anticipates, believes, estimates, expects, intends, may, plans, projects, will, would and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. We may not actually achieve the plans, intentions, or expectations disclosed in our forward-looking statements and you should not place undue reliance on our forward-looking statements. Actual results or events could differ materially from the plans, intentions and expectations disclosed in the forward-looking statements that we make. These forward-looking statements involve risks and uncertainties that could cause our actual results to differ materially from those in the forward-looking statements, including, without limitation, changes in need and market opportunity for any tests developed through this pipeline initiative may impact our estimated total U.S. market opportunity, delays in clinical studies may delay our ability to launch our pipeline test, our pipeline test may not be as effective as anticipated, the effects of the COVID-19 pandemic on our business and our efforts to address its impact on our business, changes in the competitive landscape and introduction of competitive products, subsequent study results and findings that contradict earlier study results and findings, the level and availability of reimbursement for our products, our ability to manage our anticipated growth and the risks set forth in our Annual Report on Form 10-K for the year ended December 31, 2019, and in our other filings with the SEC. The forward-looking statements are applicable only as of the date on which they are made, and we do not assume any obligation to update any forward-looking statements, except as may be required by law.

View source version on businesswire.com: https://www.businesswire.com/news/home/20210510005212/en/

Excerpt from:
Castle Biosciences Announces Pipeline Initiative to Develop Genomic Test Targeting Systemic Therapy Response in Patients with Psoriasis, Atopic...

The Psoriasis Treatment Market is expected to grow at a CAGR of 7.51% and is poised to reach US$XX Billion by 2027 as compared to US$XX Billion in 2020. The factors leading to this extraordinary growth is attributed to various market dynamics discussed in the report. Our experts have examined the market from a 360 degree perspective thereby producing a report which is definitely going to impact your business decisions.

In order to make a pre-order inquiry, kindly click on the link below:-https://decisivemarketsinsights.com/global-psoriasis-treatment-market/70093416/pre-order-enquiry

The Psoriasis Treatment market research report provides detailed information on the crucial pointers like the market overview, company profiles, market competition by leading key players, market size by regions, and the revenue generated by the major countries as well. The market research report also provides market share data of the key major leading players in the major regions and areas like North America, Europe, Asia-Pacific, the Middle East & Africa, and South America as well. The competitive strengths are well understood by the Global Info Research analysts and thus they have provided the competitive analysis for each competitor on a separate basis. The overall market is divided into segments in terms of its type and Applications.

To avail Sample Copy of report, visit @ https://decisivemarketsinsights.com/global-psoriasis-treatment-market/70093416/request-sample

By Market Players:SiemensHitachi MedicalPhilips HealthcareGE HealthcareAbbottRocheMyriad GeneticsCanon Medical SystemsDanaherQiagen

For the period 2019-2027, the growth among the various segments of the Psoriasis Treatment market, the research report provides accurate forecasts and the calculations for the sales and marketing in terms of its Type and by its Application. Thus, by targeting qualified niche markets, the market research industry report will help the clients to expand their business in terms of both value and volume as well. Pointers like Market Share Analysis, company overview, production sites and facilities, SWOT analysis, company total revenue (financials), market potential, global presence, Competitive Landscape, sales and revenue generated, market share, price, product launch are briefly described in the report.

To inquire about the discount, kindly fill the form by clicking on the link below:-https://decisivemarketsinsights.com/global-psoriasis-treatment-market/70093416/request-discount

From 2019 to 2027, the study of the research report provides the sales, market share, and revenue for each player that is well covered in the report. Rapidly changing in the infrastructure, rising maintenance costs of the market services, reducing support and maintenance complexities are the major growth factors for the market. In addition to that, the growing need for the support services of new levels and the increasing use of unified support services are the other factors that are highly responsible for driving the forces of the market. A comprehensive analysis is also conducted by the Psoriasis Treatment market research report to study the market size, volume, share and cost structure in detail and to analyze the current markets scenario of the global market

North America (USA, Canada, and Mexico) Asia-Pacific (China, Japan, Australia, New Zealand, South Korea, India, and Southeast Asia) Europe (Germany, France, the United Kingdom, Netherlands, Russia, Italy, and Rest of Europe) Middle-East and Africa (Saudi Arabia, United Arab Emirates, Israel, Egypt, Nigeria, and South Africa) South America (Brazil, Argentina, Colombia, rest of countries, etc.)

To dominate the market over the next five years due to increasing demand for new level services throughout the globe, the various Psoriasis Treatment market segments of the industry are well anticipated in the report. This is because of the need for the improvement in automation and the advancement rate in the technologies in the current and the future market scenarios. Based on the factors like deployment, enterprise size, region, industry, and service, the segmentation of the market is easily done in the report.

To inquire about the discount, kindly fill the form by clicking on the link below:-https://decisivemarketsinsights.com/global-psoriasis-treatment-market/70093416/request-discount

In the vital countries and regions, an in-depth assessment of the growth and other aspects of the market is well offered in the market research report. Some of the few countries and regions are like United States, China, Japan, Germany, France, United Kingdom, Russia Korea, India, Canada, Mexico, Italy, Southeast Asia, Australia, Brazil, and Saudi Arabia, etc. Also, on the progress of key regional markets such as North America, Europe, Asia-Pacific, South America, and the Middle East & Africa, the market research report highlights the crucial pointers as well.

Kindly contact us and our expert will get back to you within 30 minutes:

Decisive Markets InsightsSunil KumarSales HeadEmail sales@decisivemarketsinsights.comUS +18317045538UK +441256636046

Go here to read the rest:
Psoriasis Treatment Market Projected to attain Significant Growth by 2027, Key Players Danaher, Qiagen KSU | The Sentinel Newspaper - KSU | The...

iStock

The COVID-19 vaccines are here, and theyre being distributed by the millions. Chances are, you know at least one person who has received one. But as welcome as these long-awaited shots are, theyre also stirring up some controversyespecially among those in the chronic community, who (understandably) have some questions. Like are these vaccines safe for everyone? And will they interact with my medications? Also, what are the side-effect risks?

For more info on psoriasis and the COVID Vaccine, check out our Facebook Live event, here!

We hear you. And were taking your questions straight from our Facebook pages to the desks of top chronic disease experts as part of our original series #ChronicVaxFacts. Todays expert is Lisa Zaba, M.D., Ph.D., a dermatologist with Stanford Health Care in Palo Alto, CA. We asked Dr. Zaba to answer questions from psoriasis patients about the COVID vaccine.

HealthCentral: Could the COVID vaccine cause a psoriasis flare?

Lisa Zaba, M.D., Ph.D.: Single-stranded mRNA molecules, like those contained in the Pfizer and Moderna COVID-19 vaccines, are activators of innate immune cells. Binding of mRNA to innate immune cells produces a potent type I interferon (IFN) response that is thought to play a central role in inflammation in some patients with autoimmune disorders. [Specifically,] type I IFN is thought to play a role in the initiation phase of psoriasis when people first develop the disease, although chronic psoriasis is perpetuated by overactivation of a different pathway, the Th17 adaptive immune response.

So in short, it is unknown how these new vaccines will affect patients with psoriasis, but major rheumatologic societies, including the National Psoriasis Foundation COVID-19 task force and the American College of Rheumatology, have put out statements indicating that the benefits of vaccination outweigh the risks for patients with psoriasis.

HC: Could the vaccine interact with my medications in any way?

Dr. Zaba: People taking immunosuppressive medications for their autoimmune diseases need those medications to stay in a remission. However, it is possible that those drugs may blunt the immune response to the COVID-19 vaccines, [possibly making them less effective]. It is not currently recommended that people stop their immunosuppressive medications prior to getting vaccinated; however, this is a discussion that should be had on a case-by-case basis with your treating doctor.

HC: Is one vaccine better than the other for people with psoriasis?

Dr. Zaba: Pfizer and Moderna mRNA vaccines are similar in composition and structure, and it is therefore unlikely that there will be a significant difference is the side-effect profile for patients with psoriasis.

HC: Will the vaccine side effects be more severe because of my condition?

Dr. Zaba: It is currently not known if the vaccine side effects will differ in those with autoimmune conditions. Immunocompromised individuals or those requiring immunosuppressive therapy were excluded from phase III SARS Cov-2 vaccine trials. Therefore, safety and efficacy in this population is unknown.

HC: What are scientists doing to get that data on vaccine safety for people with our condition, and when will we have access to that information?

Dr. Zaba: Although vaccination is likely much safer for autoimmune patients than becoming infected with SARS CoV-2 virus, there are currently no NIH or pharmaceutical funded vaccine trials specifically looking at the question of safety and efficacy of COVID-19 vaccines in patients with autoimmunity. Our aim [at Stanford] is to conduct an observational study of COVID-19 vaccines in autoimmune patients under the close supervision of doctors specializing in autoimmunity.

Meet Our Writer

Sarah Ellis is a wellness and culture writer who covers everything from contraceptive access to chronic health conditions to fitness trends. She is originally from Nashville, Tennessee and currently resides in NYC. She has written for Elite Daily, Greatist, mindbodygreen and others. When shes not writing, Sarah loves distance running, vegan food, and getting the most out of her library card.

Original post:
COVID Vaccines & Psoriasis: What To Know